Drug-induced cholestasis is mostly intrahepatic and characterized by alterations of bile canaliculi dynamics and morphology as well as accumulation of bile acids (BAs) in hepatocytes. However, little information exists on first changes in BA content and profile induced by cholestatic drugs in human liver. In this study, we aimed to analyze the effects of a large set of cholestatic and noncholestatic drugs in presence of physiological serum concentrations and 60-fold higher levels of 9 main BAs on cellular accumulation of BAs using HepaRG hepatocytes. BAs were measured in cell layers (cells þ bile canaliculi) and culture media using high-pressure liquid chromatography coupled with tandem mass spectrometry after 24 h-treatment. Comparable changes in total and individual BA levels were observed in cell layers and media from control and noncholestatic drug-treated cultures: unconjugated BAs were actively amidated and lithocholic acid (LCA) was entirely sulfated. In contrast, cellular accumulation of LCA and in addition, of the 2 other hydrophobic BAs, chenodeoxycholic acid and deoxycholic acid, was evidenced only with cholestatic compounds in presence of BA mixtures at normal and 60-fold serum levels, respectively, suggesting that LCA was the first BA to accumulate. Cellular accumulation of hydrophobic BAs was associated with inhibition of their amidation and for LCA, its sulfation. In conclusion, these results demonstrated that cellular accumulation of unconjugated hydrophobic BAs can be caused by various cholestatic drugs in human hepatocytes and suggest that their cellular detection, especially that of LCA, could represent a new strategy for evaluation of cholestatic potential of drugs and other chemicals.
Cholestasis is typified by accumulation of bile acids (BAs) or their conjugated bile salts in the liver and systemic circulation. Both intrahepatic and extrahepatic cholestasis of various etiologies have been described in humans; they may be due to impaired secretion of BAs by hepatocytes or obstruction of either intrahepatic or extrahepatic bile ducts. Accumulation of pigmented material in hepatocytes and the lumen of bile canaliculi (BCs) and some irregularly dilated BCs with conspicuous alterations of microvilli have been visualized in cholestatic liver (Layden et al., 1975) .
Cholestasis is associated with an increase in serum BA content that can reach 60-fold or more normal values as well as with major changes in BA profiles (Humbert et al., 2012; Trottier et al., 2012 ). An increase in serum BA conjugates has been observed in intrahepatic cholestasis of pregnancy (Castano et al., 2006; Reyes and Sjovall, 2000; Tribe et al., 2010) , obstructive cholestasis (Woolbright et al., 2015) , and in infants with biliary atresia (Abukawa et al., 1998) . In contrast, BA content is decreased in bile compared with normal values but is still much higher than in serum in cholestatic patients (Humbert et al., 2012; Woolbright et al., 2015) . Unconjugated secondary hydrophobic BAs are decreased in serum of cholestatic patients versus healthy subjects (Humbert et al., 2012) .
Data on total content and profile of BAs in normal and cholestatic human liver are scarce compared with those in serum and bile (Garcia-Canaveras et al., 2012) . A marked increase in total and unconjugated BAs has been found in the liver of young infants with biliary atresia (Abukawa et al., 1998) and in chronic cholestatic liver disease (Fischer et al., 1996) .
Primary BAs, namely cholic acid (CA) and chenodeoxycholic acid (CDCA), are synthesized in hepatocytes from cholesterol by 2 multistep pathways. They are then conjugated to glycine or taurine, giving rise to taurocholic acid (TCA), glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), and taurochenodeoxycholic acid (TCDCA). These conjugated (amidated) BAs may also be metabolized by different liver enzymes such as cytochrome P450s, and glucuronosyl-and sulfo-transferases (Chiang, 2009) . After secretion into bile via canalicular transporters, mainly the bile salt export pump (BSEP), conjugated BAs are released into the duodenum, where they facilitate the absorption of dietary lipids and liposoluble vitamins. The gut microbiota catalyzes 7a-dehydroxylation of CDCA and CA to generate the secondary BAs, namely lithocholic acid (LCA) and deoxycholic acid (DCA) (Monte et al., 2009) . Around 95% of both primary and secondary BAs can be reabsorbed and return back to the liver via the enterohepatic circulation (Anwer, 2014; Chiang, 2009) .
Many drugs can induce intrahepatic and more rarely extrahepatic cholestasis in a minority of patients. As in cholestasis of other etiologies changes in total BAs and profiles have been reported in both serum and bile of patients suffering from druginduced cholestasis. In contrast, there is little information on early changes in BA total content and profiles in human liver exposed to cholestatic drugs. Indeed, the first steps cannot be analyzed in humans and differences in BA synthesis, regulation and composition with animals limit the interest of these latter (Chiang, 2009 ). In support, many drugs can cause cholestasis in humans without inducing any significant liver injury in preclinical animal models (Fattinger et al., 2001 ). An increase in hydrophobic BAs, ie, CDCA, LCA, and DCA, is thought to cause liver injury (Woolbright et al., 2015) . However, molecular mechanisms by which BAs induce liver injury remain poorly elucidated.
BC dynamics are impaired during cholestasis; this alteration is associated with disruption of the Rho/Myosin light chain kinases (ROCK/MLCK) signaling pathway, actin cytoskeleton rearrangement, BC deformations and cellular accumulation of BAs . Several molecular targets of the tested cholestatic compounds have been identified in the ROCK/MLCK pathway (Burban et al., , 2018 Sharanek et al., 2016) . Recently, we reported that in presence of physiological serum BA concentrations, 3 major cholestasis drugs, namely cyclosporine A (CsA), chlorpromazine (CPZ), and troglitazone (TRO), induced preferential cellular accumulation of the 3 major hydrophobic BAs, ie, LCA, DCA, and CDCA, in their unconjugated forms, using differentiated HepaRG cells. Importantly, these 3 drugs can cause irreversible constriction whereas many other cholestastic drugs are causing dilatation of BCs (Antherieu et al., 2013; Burban et al., , 2018 Burbank et al., 2016; Sharanek et al., 2016) , leading to question whether rapid intracellular accumulation of hydrophobic BAs is a general feature induced by cholestatic drugs. In this study, using a large set of cholestatic and noncholestatic compounds, we show that only cholestatic drugs caused cellular accumulation of hydrophobic BAs after a short treatment in the presence of exogenous BAs.
MATERIALS AND METHODS
Reagents. Flucloxacillin (FLX), levofloxacin (LVX), erythromycin (ERY), ampicillin (AMP), streptomycin (SM), perhexiline (PER), troglitazone (TRO), amiodarone (AMI), acetaminophen (APAP), and methylthiazol tetrazolium (MTT) were purchased from Sigma (St. Quentin Fallavier, France). Macitentan (MAC) and sitaxentan (SIT) were provided by Alsachim (IllkirchGraffenstaden, France). Bosentan (BOS) was obtained from Sequoia Research Products (Pangbourne, UK). Fasudil (FAS) (HA-1077) was from BPS Bioscience (Le Perray en Yvelines, France). Ambrisentan (AMB) was a gift from MSN Laboratories (Sanath Nagar, India). Other chemicals were of reagent grade.
HepaRG cell cultures and treatments. All HepaRG cell cultures were prepared from vials of the same frozen cell batch and incubated with the same HyClone fetal calf serum. Before starting the treatments HepaRG cells were differentiated as previously described in Cerec et al. (2007) . Briefly, cells were seeded at a density of 2.6 Â 10 4 cells/cm 2 in Williams' E medium supplemented with 2 mM glutamax, 100 U/ml penicillin, 100 lg/ml streptomycin, 10% HyClone fetal calf serum, 5 lg/ml insulin, and 50 lM hydrocortisone hemisuccinate. After 2 weeks they were shifted to the same medium supplemented with 1.7% dimethyl sulfoxide (DMSO) for 2 additional weeks to obtain confluent differentiated cultures containing around equal proportions of hepatocytelike and progenitor/primitive biliary-like cells. For measurement of BAs cultures were prepared in 10 cm petri dishes. The medium was supplemented with 2% fetal bovine charcoal-stripped serum (BA-free serum) (Sigma, reference: F6765) and DMSO concentration was reduced to 1%. No individual BA was detected in charcoal-stripped serum. The cultures were first incubated for 24 h in this medium in presence of BA mixtures alone to favor elimination of bovine BAs that were previously accumulated into the cells and because cholestatic drugs can alter BA uptake; then they were co-exposed to BA mixtures and the tested compounds for additional 24 h. BA mixtures were composed of 9 individual BAs at either concentrations found in the serum of normal individuals (1Â) or 60-fold higher concentrations (60Â). These BAs included CA, CDCA, and their taurine and glycine conjugates; DCA and its glycine conjugates and LCA (Table 1) . The choice of 24 h-drug treatment was based on previous results . Of note, if total BA content in the serum of patients suffering from chronic cholestatic diseases can reach 60-fold or more that measured in the serum of healthy individuals the relative changes in individual BAs are quite variable. Primary BA content is usually hugely increased whereas that of secondary BAs is frequently decreased (Humbert et al., 2012; Masubuchi et al., 2016; Tribe et al., 2010; Trottier et al., 2012) . However, a significant increase in total serum LCA and DCA has been reported in pregnant women with intrahepatic cholestasis (Lucangioli et al., 2009 ) and levels of conjugated LCA were found 30-to 40-fold higher in serum of heart transplant patients with chronic hepatitis compared with transplant patients without hepatitis and non-transplant patients with chronic hepatitis after treatment with CsA (Myara et al., 1996) . Moreover, the amounts of total LCA, DCA, and CDCA in the 60Â-BA mixture, ie, 1.8, 51.6, and 135.6 mM, respectively, remained much lower than their corresponding in vitro cytotoxic concentrations (Sharanek et al., 2015; Woolbright et al., 2015) .
Cell viability. Cytotoxicity was evaluated using the MTT colorimetric assay. Briefly, the cells were seeded in 96-well plates and treated with the tested compounds in presence of the 60Â-BA mixture for 24 h. After medium removal, 100 ll of serum-free medium containing MTT (0.5 mg/ml) was added to each well and incubated for 2 h at 37 C. The water-insoluble formazan was dissolved in 100 ll DMSO, and absorbance was measured at 550 nm.
Sample preparation and measurement of BAs. Standard BA stock solutions were prepared in methanol at a concentration of 1 mg ml À1 and stored in a sealed container at À20 C. The stock solutions were pooled and diluted to obtain mixed-calibration BA solutions with concentrations ranging from 31.3 ng ml À1 to 31.3 mg ml À1 . Standard solutions were available for 28 BAs (Supplementary Table 1 ). Both cells (by gentle scrapping) and culture media (supernatants) were collected from HepaRG cell cultures treated with the 13 tested compounds plus TRO used as a positive control, in the presence of either 1Â-or 60Â-BA mixture. Before analysis, the samples were lyophilized, and then 1 ml of water was added to the dried samples, homogenized using a PolyTron homogenizer for 30 s and clarified by centrifugation at 20 000 Â g for 20 min. The supernatants were collected and extracted using a solid phase extraction (SPE) cartridge. BA content was measured using high-pressure liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). The chromatographic separation of BAs was carried out on a Zorbax eclipse XDB-C18 (Agilent Technology, Garches, France) fitted on an Agilent 1100 HPLC system as previously described for human samples (Humbert et al., 2012) Data analysis. The amounts of total and individual BAs were measured in both cell layers and supernatants. HepaRG hepatocytes represent around 50% of total cells in differentiated cultures (Cerec et al., 2007) . Because primitive biliary cells do not express BA metabolizing enzymes and transporters and do not accumulate BAs (Sharanek et al., 2014 (Sharanek et al., , 2015 , they were neglected for calculation of BA content. Each 10 cm dish was estimated to contain around 7 Â 10 6 cells of which 3.5 Â 10 6 HepaRG hepatocytes. To keep the same unit BA values were expressed as mg/10 6 hepatocytes in both cell layers and supernatants.
Statistical analysis. One-way ANOVA with Bonferroni's multiple comparison test (GraphPad Prism 5.00) was performed to compare data. Each value corresponded to the mean 6 standard deviation (SD) of 3-independent experiments. Data were considered significantly different when p < .05.
RESULTS

Metabolism of Exogenous Bile Acids by HepaRG Hepatocytes
Differentiated HepaRG cells were first incubated for 24 h in a medium containing 2% BA-free serum and 1% DMSO and supplemented with the mixture of 9 major BAs either at concentrations found in serum of normal individuals (1Â) or at 60-fold higher concentrations (60Â), and then concomitantly with the tested drugs in the same medium for additional 24 h. As previously observed , in our experimental The 1Â and 60Â mixtures of individual BAs and quantities recovered after addition to unexposed culture media. The 1Â-BAs represent physiological (normal) serum concentrations (Scherer et al., 2009 ) and 60Â-BAs correspond to 60-fold higher concentrations of each BA. Corresponding quantity of each individual BA available for 10 6 hepatocytes was calculated using the following formula: Quantity (mg/10 6 hepatocytes) ¼ Concentration * molecular weight * volume of medium/number of hepatocytes. Based on medium volume ¼ 10 ml and number of hepatocytes ¼ 3.5*10 6 hepatocytes per dish.
conditions 1Â-and 60Â-BA mixtures did not induce obvious cellular injury. No significant cytotoxicity was observed using the MTT assay and only slight dilatation of BCs and/or some lipid droplets were seen in hepatocyte-like cells, if any (Figure 1 ). Total 1Â-and 60Â-BA contents measured in unexposed media corresponded to 3.56 mM (or 4.48 mg/10 6 HepaRG hepatocytes) and 178.63 mM (or 224.89 mg/10 6 HepaRG hepatocytes), respectively (Table 1) . After the second 24 h incubation of HepaRG cell cultures with 1Â-and 60Â-BA mixtures 4.88 6 0.58 and 264.9 6 31.9 mg per 10 6 HepaRG hepatocytes were recovered in supernatants þ cell layers, respectively (Table 2) . These values included cellular accumulated BAs at the time of medium renewal with BA mixtures. BA contents in cell extracts of untreated (control) cultures represented less than 7% in both conditions. The amount of neo-synthesized BAs during this period was limited . Nearly all unconjugated CA, CDCA, and DCA added to the 1Â-BA mixture were conjugated, mainly to taurine whereas LCA was completely sulfated in control cultures after the second 24 h incubation. No amidated LCA was detected. The BA mixture did not contain TDCA. Changes in glycine conjugates were limited, if any (Table 3) .
Unconjugated BAs added in the 60Â-mixture were also metabolized; indeed, unconjugated CDCA, DCA, and CA levels were reduced and those of conjugated BAs were increased. LCA was nearly completely sulfated of which around 50% was conjugated to taurine (Table 3 ). 
Effects of the Tested Compounds on Cellular Accumulation of BAs in Presence of Exogenous BAs
Seven out of the 13 new tested compounds were previously found to impair BC dynamics, causing dilatation or constriction, and were classified as cholestatic, namely FLX, BOS, PER, FAS, LVX, ERY, and MAC. The 6 others did not affect BC morphology and were classified as noncholestatic (SM, SIT, APAP, AMI, AMB, and AMP), in agreement with clinical observations ; they corresponded to 3 hepatotoxic (AMI, APAP, SIT) and 3 nonhepatotoxic (SM, AMB, AMP) compounds. In addition, TRO was used as a positive cholestatic drug to make direct comparison with our previously reported observations . Drugs were added at the following concentrations: TRO, BOS, FAS, ERY, MAC, PER, AMI: 10 mM; FLX: 0.5mM; LVX, AMB, SIT: 50 mM; SM, AMP, APAP: 2 mM (Table 4 ). These concentrations were selected from preliminary dose-response cytotoxicity studies. Because the 60Â-BA mixture-enhanced cytotoxicity induced by hepatotoxic drugs lower concentrations than those previously selected for evaluation of their effects on BC dynamics and morphology, had to be used. In the current experimental conditions, in absence or presence of BA mixtures, dilatation of BC was observed in HepaRG hepatocytes treated with most cholestatic drugs, especially FAS and FLX. No other obvious morphological changes and no significant decrease in MTT values were evidenced after 24 h treatments (Figure 1 ). Comparable total BA levels (supernatants þ cell layers) were recovered after incubation of the cultures with either BA mixtures whatever the culture condition (drug treatment or not) ( Table 2) . 
Effects of Noncholestatic Drugs
Whether incubated in the presence of 1Â-or 60Â-BA mixtures, cultures treated with noncholestatic drugs exhibited comparable changes to those observed in cultures treated with drugs only. Comparable BA values (total and individual BAs) to those measured in control cultures were found in cultures treated with noncholestatic drugs for 24 h (Table 2) . Nearly all CA, CDCA, and DCA that were present in the 1Â-BA mixture, were conjugated whereas LCA was completely sulfated. No amidated LCA was detected. A large fraction of CA and DCA added to the 60Â-BA mixture was also conjugated to taurine; CDCA was only partly conjugated and LCA was mostly sulfated, as either 3S-LCA or 3S-TLCA at nearly equal percentages. Both forms of LCA were present mostly in the supernatants and only as traces in cell layers of untreated cultures. In addition, low amounts of unconjugated/unsulfated LCA were detected in supernatants from cultures treated with APAP, AMI, and AMB. Levels of cellular unconjugated BAs found with noncholestatic drugs were comparable with those measured in control cultures (Figs. 2-4 and Supplementary Tables 2 and 3).
Effects of Cholestatic Drugs in Presence of the 13-BA Mixture
Among the 7 new tested cholestatic drugs only FAS showed a significant cellular increase (2.4-fold) in total BAs, peaking at 0.69 mg, a value close to that found with TRO ( Figure 2A ). These major changes in total BAs observed with TRO and FAS were associated with marked increase in unconjugates/conjugates ratios of hydrophobic BAs. Indeed, in supernatants from TRO-and FAS-treated cultures levels of unconjugated CDCA were around 30-fold higher whereas those of its conjugates (TCDCA and GCDCA) were reduced when compared with the values obtained with other cholestatic drugs ( Figure 2B ). Marked unconjugated DCA levels were detected only in supernatants of TRO-treated cultures (0.2 mg) and in parallel, conjugates were reduced by around 35%-45% (TDCA) or 20%-30% (GDCA). Importantly, cellular accumulation of unconjugated CDCA and DCA was evidenced only with these 2 drugs, ie, 0.05 and 0.11 mg with TRO and 0.04 and 0.03 mg with FAS, respectively ( Figure 2C and Supplementary Table 2). Although it was not added in the mixture, TDCA was detected in both supernatants and cell layers at comparable levels in all samples, except in those from TROtreated cultures (Supplementary Table 2) .
Although LCA was undetectable in cell layers from untreated cells, it represented 17.5, 7.5, 5, 6, 10, 7, 7, and 2 ng/10 6 hepatocytes in cell layers of TRO, FLX-, BOS-, PER-, FAS-, LVX-, ERY-, and MAC-treated cultures respectively, after 24 h, ( Figure 2D ). Total LCA was found in its sulfated form, except in TRO-treated cultures. Indeed in these latter, unsulfated LCA was detected in both supernatants and cell layers ( Figure 2E ); in parallel, the levels of sulfated LCA were strongly decreased (> 60%, corresponding to around 0.03 mg) in supernatants (Figs. 2E and 2F) . Much more limited changes were observed in CA levels. Unconjugated CA was increased around 3 times in supernatants of TRO-and FAS-treated cells and traces were detected in cell layers of TRO-treated cells only ( Figure 2G ).
Effects of Cholestatic Drugs in Presence of the 603-BA Mixture A 1.7-to 2.7-fold increase in total BAs was evidenced in cell layers of HepaRG cell cultures treated with cholestatic drugs, in presence of the 60Â-BA mixture when compared with corresponding controls ( Figure 3A) . The value measured with TRO was similar to that found with most other cholestatic drugs. In parallel, BA levels were decreased in supernatants. Accordingly, major changes were observed in cellular and supernatant profiles of hydrophobic BAs from cultures treated with cholestatic drugs. Enhanced cellular accumulation of total BAs was associated with around 4-to 8-fold more unconjugates and 2-to 3-fold more conjugates of CDCA and DCA as well as increased unsulfated LCA ( Figure 3B ). Cellular accumulation of the 3 hydrophobic BAs, CDCA, DCA, and LCA, in their unconjugated or unsulfated forms was evidenced with the 8 cholestatic drugs (Figs. 3C and 3D and 4B; Supplementary Table 3) . LCA was the most accumulated BA. Total cellular LCA (unconjugated and sulfated forms) reached 0.23-0.61 mg, ie, 9%-24% of total LCA. Unsulfated LCA represented 0.06-0.27 mg (Figs. 4A and 4B) . In corresponding supernatant levels of unsulfated LCA reached 0.5-1.2 mg whereas only traces were detected in controls and in cultures treated with noncholestatic molecules, if any (Figs. 4C  and 4D ).
Limited changes were observed in CA profiles in cultures treated with cholestatic compounds. Importantly, unconjugated CA was evidenced only in supernatants ( Figure 4F ).
DISCUSSION
Many drugs are known to induce cholestasis in a minority of patients but little information exists on accumulation of toxic BAs in the liver. In this study, using a large set of cholestatic and noncholestatic drugs we show that only the former caused preferential cellular accumulation of hydrophobic BAs in HepaRG hepatocytes after 24 h-co-exposure with a mixture of exogenous BAs at concentrations usually found in serum of healthy subjects and/or at 60-fold higher concentrations. CDCA and DCA preferentially accumulated as unconjugates and LCA in its unsulfated form.
Intrahepatic accumulation of hydrophobic BAs is considered as the hallmark of cholestasis. CDCA, DCA, LCA, and GCDCA have been reported to be highly cytotoxic in rodents, and their accumulation can damage hepatic cells by inducing mitochondrial dysfunction, oxidative stress, or apoptosis (Malhi et al., 2010) . However, hydrophobic BAs are much less hepatotoxic in human than in various animal species (Hofmann, 2004; Woolbright et al., 2015) . In agreement, after 24-h exposure, GCDCA was found to cause necrosis of primary human hepatocytes (Woolbright et al., 2015) and LCA to be cytotoxic to HepaRG cells (Sharanek et al., 2015) , only at concentrations of 1 mM and 100 mM, respectively. Overall BA concentrations in serum and bile usually observed during cholestasis in vivo ranged from 1 to 20 mM and 1 to 5 mM, respectively (Woolbright et al., 2015) ; consequently, serum levels must be supplemented with hydrophobic BAs to become hepatotoxic to isolated hepatocytes and liver cell lines.
Addition of BAs to the medium is a prerequisite to detect accumulation in in vitro hepatocytes. Indeed, in BA-free medium the amounts of neo-synthesized BAs are limited and strongly reduced by cholestatic drugs (Sharanek et al., 2015) . Total cellular BAs could reach 50 mg/10 6 hepatocytes after 24 h-treatment with cholestatic drugs compared with 17 mg/10 6 hepatocytes in corresponding untreated cultures, in presence of the 60Â-BA mixture, without evidence of cellular injury. Comparable cellular accumulation of BAs was obtained with CsA, CPZ, and TRO . Altogether, these data favor the conclusion that in our in vitro experimental conditions cholestatic drugs can cause features of cholestasis in absence of marked cellular damage and agree with the prolonged survival of hepatocytes in cholestatic livers despite high intrahepatic and serum BA levels. However, importantly when higher noncytotoxic cholestatic drug concentrations were used morphological alterations that included accumulation of intracytoplasmic lipid droplets and detachment of primitive biliary cells, occurred in presence of the 60Â-BA mixture after 24 h co-treatment, reflecting mixed hepatocellular-cholestatic lesions (not shown). Recent studies have shown that BAs might induce liver cell injury either in vitro or in vivo in an inflammatory context (Cai et al., 2017; Hao et al., 2017; Woolbright and Jaeschke, 2016) . It might be hypothesized that in presence of pro-inflammatory cytokines or innate immune cells HepaRG cells will be more sensitive to cellular accumulation of BAs caused by cholestatic drugs. This important question warrants further investigation. HepaRG cells actively conjugated BAs as shown by disappearance of unconjugated CDCA, DCA, and CA and appearance of large amounts of corresponding conjugates in presence of BA mixtures after 24 h-incubation. Preferential formation of taurine conjugates from the 3 BAs agrees with previous observations .
Major differences were observed in supernatant/cell extract ratios and profiles of BAs in cultures treated with cholestatic drugs compared with cultures that were either untreated or treated with noncholestatic compounds, especially in presence of the 60Â-BA mixture. When using a medium containing the major BAs at concentrations found in the serum of healthy subjects peculiar changes in BA profiles were evidenced with 2 out of the tested cholestatic drugs, ie, TRO and FAS; that were mainly characterized by lower conjugation of CDCA and CDA associated with reduced accumulation of taurine and glycine conjugates in the supernatants. However, the most important changes observed in presence of 1Â-BA mixture concerned LCA, the most lipophilic BA, that was detected in cell layers from cultures treated with all cholestatic drugs. Noteworthy, cellular LCA was previously evidenced in cultures treated with CPZ, CsA, and TRO after 4 h in presence of 1Â-BA mixture ; it was also detected in HepaRG cells after 4 and 24 h treatment with 10 or 50 mM CsA in presence of 2% bovine serum, containing 16.8 6 3.3 nM LCA, ie, around 1.8 ng/10 6 hepatocytes (Sharanek et al., 2015) . Altogether, these results suggest that LCA is the first hydrophobic BA to accumulate in hepatocytes treated with cholestatic drugs. More extensive changes were found with all tested cholestatic drugs after 24 h-co-incubation with the 60Â-BA mixture. They were typified by more unconjugated BAs (CDCA, CA, and DCA), lower amounts of their taurine and glycine conjugates and presence of unsulfated LCA in supernatants and in parallel, preferential accumulation of unconjugated CDCA and DCA and unsulfated LCA in cell layers, favoring the conclusion that inhibition of BA amidation and sulfation activities could be a common effect of cholestatic drugs. In support, gene expression of the conjugating CoA: amino acid N-acyltransferase (BAAT) was found to be inhibited by 36% and 84% after 4 and 24 h treatment with 50 mM CsA in a medium containing 2% bovine serum and 1% DMSO, respectively (Sharanek et al., 2015) . Further studies are warranted to determine the precise mechanisms by which conjugation and sulfation of BAs are inhibited by cholestatic drugs.
In addition to unconjugated LCA, cellular accumulation of 3S-TLCA and 3S-LCA was evidenced after treatment with all cholestatic drugs at variable levels in presence of the 60Â-BA mixture. Noticeably, cellular LCA content (unconjugated LCA, 3S-TLCA, and 3S-LCA) represented > 21% with TRO, BOS, and FLX, 3 potent cholestatic drugs, versus 15% or less with other cholestatic drugs, of total recovered LCA (cell layers þ supernatants). These data suggest that in addition to inhibition of LCA sulfation cholestatic drugs reduced excretion of the sulfated forms. Intracellular accumulation of 3S-TLCA could result from inhibition of its efflux transport.
Although also specifically observed with cholestatic drugs the increase in cellular unconjugated CA was lower compared with unconjugated hydrophobic BAs. Contrary to the latter that freely diffuse across membranes, CA requires a carrier for hepatocyte uptake (Hofmann, 2004) ; this could lead to a lower uptake and consequently lower accumulation in HepaRG hepatocytes.
The cholestatic drugs included the recently marketed endothelin receptor antagonist MAC. Despite no known or suspected cases of cholestasis in treated patients suffering from pulmonary arterial hypertension it was demonstrated to exhibit similar hepatotoxic and cholestatic properties to bosentan, using HepaRG hepatocytes. Its similar chemical structure to bosentan, was advanced to sustain its in vitro cholestatic properties (Burbank et al., 2017) . Its ability to cause cellular accumulation of unconjugated BAs supports its classification as a cholestatic drug. Noteworthy, a first case of acute liver failure with a process of micronodular cholestatic cirrhosis was recently associated with MAC treatment (Tran et al., 2018) . Many cholestatic drugs have been identified as inhibitors of the bile salt export pump (BSEP) using inverted membrane vesicles (Dawson et al., 2012; Morgan et al., 2010; Pedersen et al., 2013) . However, false positives and false negatives have been found (Pedersen et al., 2013) . For instance, the potent cholestatic CPZ was classified as a non BSEP inhibitor and the noncholestatic AMI as a weak BSEP inhibitor (Morgan et al., 2010) . Interestingly, our results demonstrate that measurement of cellular toxic hydrophobic BAs allowed to correctly classify CPZ and AMI as cholestatic and noncholestatic, respectively. Recently, Chan and Benet examined several published BSEP inhibition datasets and concluded that this assay is not predictive of cholestatic potential of drugs (Chan and Benet, 2018) . Another assay, the drug-induced cholestasis index, based on inhibition of urea production in sandwich-cultured human hepatocytes co-exposed to drugs and a BA mixture, has been proposed to identify drugs with cholestatic risk (Oorts et al., 2016) . This index likely reflects BA-enhanced sensitivity to hepatotoxic compounds; compared with our own approach it usually requires higher drug concentrations and does not identify all cholestatic drugs.
Recently, adverse outcome pathways (AOPs) have been introduced as new tools to gain knowledge on the mechanism basis of toxicity. They include molecular initiating events and a series of key intermediate events, leading to a toxic effect. The first AOP for cholestasis was based on the inhibition of BSEP (Vinken et al., 2013) . Because this assay does not reflect a general mechanism of cholestatic drugs mechanistic modeling of cholestasis in AOP networks are now considered as more appropriate. Our previous and present studies have identified new key events that have been observed with all the hitherto tested potent cholestatic drugs; ie, deregulation of the ROCK-MLCK pathway, impairment of BC dynamics associated with disruption of pericanalicular actin filaments, that, in addition to inhibition of transporters, can result in preferential cellular accumulation of toxic hydrophobic BAs. All these key events could be used to define new AOPs for cholestasis.
In summary, our results show that cholestatic drugs can specifically cause rapid and preferential accumulation of toxic hydrophobic BAs, especially LCA, in HepaRG hepatocytes and that the huge increase in unconjugated versus conjugated forms, appears to reflect what is occurring in cholestatic livers (Abukawa et al., 1998; Fischer et al., 1996) .Together with BC dynamics impairment cellular accumulation of these BAs could represent potent biomarkers of the cholestatic potential of new compounds and could be used to test therapeutics for cholestatic liver injury. Cellular BA accumulation could be measured not only by HPLC-MS/MS but also by the use of fluorescent BA probes. These results give further support to the suitability of differentiated HepaRG cells for investigations on mechanisms of drug-induced cholestasis as well as for other toxicity studies .
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